KR101544246B1 - 프로스타시클린 유사체의 고체 제제 - Google Patents

프로스타시클린 유사체의 고체 제제 Download PDF

Info

Publication number
KR101544246B1
KR101544246B1 KR1020117028834A KR20117028834A KR101544246B1 KR 101544246 B1 KR101544246 B1 KR 101544246B1 KR 1020117028834 A KR1020117028834 A KR 1020117028834A KR 20117028834 A KR20117028834 A KR 20117028834A KR 101544246 B1 KR101544246 B1 KR 101544246B1
Authority
KR
South Korea
Prior art keywords
delete delete
less
months
package
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117028834A
Other languages
English (en)
Korean (ko)
Other versions
KR20120017058A (ko
Inventor
케네스 로버트 파레스
Original Assignee
유나이티드 세러퓨틱스 코오포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101544246(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유나이티드 세러퓨틱스 코오포레이션 filed Critical 유나이티드 세러퓨틱스 코오포레이션
Publication of KR20120017058A publication Critical patent/KR20120017058A/ko
Application granted granted Critical
Publication of KR101544246B1 publication Critical patent/KR101544246B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117028834A 2009-05-07 2010-05-06 프로스타시클린 유사체의 고체 제제 Active KR101544246B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17626809P 2009-05-07 2009-05-07
US61/176,268 2009-05-07

Publications (2)

Publication Number Publication Date
KR20120017058A KR20120017058A (ko) 2012-02-27
KR101544246B1 true KR101544246B1 (ko) 2015-08-12

Family

ID=43050464

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028834A Active KR101544246B1 (ko) 2009-05-07 2010-05-06 프로스타시클린 유사체의 고체 제제

Country Status (7)

Country Link
US (1) US8349892B2 (https=)
EP (1) EP2427054A4 (https=)
JP (1) JP5649645B2 (https=)
KR (1) KR101544246B1 (https=)
CN (1) CN102421288B (https=)
CA (1) CA2760499C (https=)
WO (1) WO2010129757A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622471T5 (es) 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
EP2026816B1 (en) 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
CN101903324B (zh) 2007-12-17 2013-07-03 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法
ES2611187T3 (es) 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
JP6046034B2 (ja) 2010-06-03 2016-12-14 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの製造
US20120004307A1 (en) * 2010-06-15 2012-01-05 United Therapeutics Corporation Oral treatment of digital ischemic lesions
US20130345471A1 (en) 2011-03-02 2013-12-26 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193627B (zh) * 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
CN109608326A (zh) 2013-03-15 2019-04-12 联合治疗公司 曲前列环素的盐
JP6263604B2 (ja) 2013-03-25 2018-01-17 ユナイテッド セラピューティクス コーポレイション チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
IL298591A (en) 2020-06-09 2023-01-01 United Therapeutics Corp Pomeryl dictopiperidine prodrugs of treprostinil
KR20250133451A (ko) 2020-12-14 2025-09-05 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
JP2024510930A (ja) 2021-03-03 2024-03-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに(e)-3,6-ビス[4-(n-カルボニル-2-プロペニル)アミドブチル]-2,5-ジケトピペラジン(fdkp)を含む乾燥粉末組成物
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A4 (en) 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Treprostinil Gentle Inhalation Mist
EP4652151A1 (en) 2023-01-19 2025-11-26 United Therapeutics Corporation Treprostinil analogs
CN117800845B (zh) * 2023-03-28 2026-04-14 广州楷石医药有限公司 一种羟基取代曲前列尼尔衍生物、合成方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079383A1 (en) 2006-12-21 2008-07-03 Concert Pharmaceuticals Inc. Prostacyclin derivatives

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
KR100638684B1 (ko) * 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6700025B2 (en) * 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
ATE441418T1 (de) * 2003-12-16 2009-09-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
DE602004028155D1 (de) * 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
KR100908547B1 (ko) * 2005-02-22 2009-07-20 화이자 인코포레이티드 5ht4 수용체 작용제로서의 옥시인돌 유도체
US20060222792A1 (en) * 2006-04-21 2006-10-05 Chemagis Ltd. Temozolomide storage system
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
EP2026816B1 (en) * 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090281129A1 (en) * 2006-05-15 2009-11-12 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof
JP2010518122A (ja) * 2007-02-09 2010-05-27 ユナイテッド セラピューティクス コーポレーション 間質性肺疾患および喘息のためのトレプロスチニル処置
US8246950B2 (en) * 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
CN101903324B (zh) * 2007-12-17 2013-07-03 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079383A1 (en) 2006-12-21 2008-07-03 Concert Pharmaceuticals Inc. Prostacyclin derivatives

Also Published As

Publication number Publication date
CN102421288A (zh) 2012-04-18
US8349892B2 (en) 2013-01-08
JP2012526140A (ja) 2012-10-25
KR20120017058A (ko) 2012-02-27
US20100282622A1 (en) 2010-11-11
JP5649645B2 (ja) 2015-01-07
WO2010129757A1 (en) 2010-11-11
CA2760499C (en) 2015-11-03
EP2427054A4 (en) 2014-01-15
CA2760499A1 (en) 2010-11-11
EP2427054A1 (en) 2012-03-14
CN102421288B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
KR101544246B1 (ko) 프로스타시클린 유사체의 고체 제제
US20250288640A1 (en) Glycopeptide compositions
IE61173B1 (en) Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations
KR20010043610A (ko) 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
US20080009537A1 (en) Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound
JP2002537258A5 (https=)
JP2013203738A (ja) 安定なボルテゾミブ製剤
JPH03153633A (ja) 2型糖尿病の予防用薬剤
NZ537944A (en) Oral administration of calcitonin prior to the consumption of food
WO2008132756A1 (en) Stable pharmaceutical compositions of ramipril
CA2653382A1 (en) A stabilised composition comprising ace inhibitors
JP4018664B2 (ja) 安定化固形製剤
CA2964524C (en) Glycopeptide compositions
JP2004073377A (ja) 固形医薬組成物中の有効成分の安定化方法
JP2004075582A (ja) 固形医薬組成物に処方される有効成分以外の成分の安定化方法
MXPA00010737A (en) Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140227

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20140227

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140625

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150325

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20140625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150325

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150224

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140227

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20150717

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20150625

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150325

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20150224

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20140227

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150806

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150806

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180718

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200715

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210715

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220718

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230705

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240703

Start annual number: 10

End annual number: 10